← Back to Clinical Trials
Recruiting NCT06685523

NCT06685523 Evaluation of Fractalkine and Its Receptor in Peri-implantitis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06685523
Status Recruiting
Phase
Sponsor Kubilay BARIŞ
Condition Peri-implantitis
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2024-11-08
Primary Completion 2025-05-08

Eligibility & Interventions

Sex All sexes
Min Age 40 Years
Max Age 60 Years
Study Type INTERVENTIONAL
Interventions
Subgingival debridementEr:YAG laser decontaminationDiyot laser decontamination

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 100 participants in total. It began in 2024-11-08 with a primary completion date of 2025-05-08.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

In this study, mechanical debridement group, Er:YAG laser group and diode laser group will be compared in terms of reducing peri-implant sulcus depth in the treatment of peri-implantitis.

Eligibility Criteria

Inclusion Criteria: * Probing depth of 4-6 mm, bone loss of at least 2 mm on X-ray and presence of inflammatory symptoms in soft tissue * No systemic disease that may affect the outcome of the treatment * Patients with healthy periodontium or patients with completed periodontal treatment * Individuals at least 6 months after prosthesis loading on the implant * Individuals who do not require further surgery for the treatment of peri-implantitis * Implants with at least 2 mm keratised gingiva * Individuals aged 40-60 years Exclusion Criteria: * Individuals undergoing radiation therapy * Individuals who smoke and drink alcohol * Individuals in pregnancy or lactation * Individuals who have received antibiotic treatment in the last three months * Individuals with parafunctional habits

Contact & Investigator

Central Contact

Kubilay Barış, Dr.

✉ kubilaybaris60@hotmail.com

📞 +90-0553-973-64-77

Frequently Asked Questions

Who can join the NCT06685523 clinical trial?

This trial is open to participants of all sexes, aged 40 Years or older, up to 60 Years, studying Peri-implantitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06685523 currently recruiting?

Yes, NCT06685523 is actively recruiting participants. Contact the research team at kubilaybaris60@hotmail.com for enrollment information.

Where is the NCT06685523 trial being conducted?

This trial is being conducted at Kirikkale, Turkey (Türkiye).

Who is sponsoring the NCT06685523 clinical trial?

NCT06685523 is sponsored by Kubilay BARIŞ. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology